logo

CLPT

ClearPoint Neuro·NASDAQ
--
--(--)
--
--(--)
1.12 / 10
Underperform

Fundamental scrutiny indicates poor standing (1.1/10). Favorable drivers: Net profit attributable to parent company shareholders / Net profit (%) and Cash-UP, balanced by issues in Net income-Revenue and Cash-MV. Investment outlook: challenging.

Fundamental(1.12)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-2.34
Score2/3
Weight-0.30%
1M Return0.09%
ROA (%)
Value-35.67
Score0/3
Weight17.02%
1M Return-7.78%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight5.72%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight8.07%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight13.93%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-47.56
Score0/3
Weight17.02%
1M Return-7.78%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight6.44%
1M Return-1.95%
Asset-MV
Value-0.50
Score0/3
Weight10.80%
1M Return-3.57%
Cash-MV
Value-0.07
Score1/3
Weight15.31%
1M Return-5.64%
Net profit / Total profit (%)
Value100.29
Score2/3
Weight6.00%
1M Return-1.71%
Is CLPT undervalued or overvalued?
  • CLPT scores 1.12/10 on fundamentals and holds a Premium valuation at present. Backed by its -86.05% ROE, -67.40% net margin, -16.53 P/E ratio, 24.10 P/B ratio, and -20.29% earnings growth, these metrics solidify its Underperform investment rating.